{"id":1072,"date":"2022-11-23T09:35:53","date_gmt":"2022-11-23T09:35:53","guid":{"rendered":"https:\/\/www.arcgroup.io\/oxford\/?p=1072"},"modified":"2023-01-16T09:11:45","modified_gmt":"2023-01-16T09:11:45","slug":"oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/","title":{"rendered":"Accession Therapeutics raises funding"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n<!-- Hero banner -->\n<section class=\"hero-banner \" id=\"block_637de3e967d4d\">\n\n    \t\t<div class=\"hero-banner__overlay\" style=\"opacity: 0.4\"><\/div>\n\t\n\t<!-- Content -->\n    <div class=\"ed-container hero-banner__content\">\n\t\t<!-- Back button -->\n\t\t\n\t\t<!-- Title -->\n                    <h1>\n                Accession Therapeutics raises funding            <\/h1>\n        \n\t\t<!-- Button -->\n            <\/div>\n\n\t<!-- Banner image -->\n            <div class=\"hero-banner__feature\">\n            <img fetchpriority=\"high\" decoding=\"async\" width=\"2560\" height=\"1707\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\" class=\"attachment-full size-full\" alt=\"\" loading=\"eager\" srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-1024x683.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-1000x667.jpg 1000w\" sizes=\"(max-width: 2560px) 100vw, 2560px\" \/>        <\/div>\n        \n    <!-- Banner video -->\n    \n    \n    <\/section>\n\n\n\n<section class=\"text-block  padding-large\" id=\"block_637de61940e53\">\n    <div class=\"ed-container\">\n        <div class=\"text-block__content\">\n                        \n\n<p id=\"viewer-6c4dk\">Oxford based <a href=\"https:\/\/www.accessiontherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Accession Therapeutics<\/a>, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has raised \u00a316.6m to advance its two lead preclinical programmes to clinical trials. New investors, including the Singaporean fund <a href=\"https:\/\/www.iglobepartners.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">iGlobe Partners<\/a>, join <a href=\"https:\/\/www.primavera-capital.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Primavera Venture Partners<\/a>, Birk Venture and biotech angels in backing the potential of the company\u2019s Trocept platform to deliver highly potent anticancer payloads with minimal toxicity. The CEO and founder of Accession Therapeutics is Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer.<\/p>\n\n\n\n<p id=\"viewer-3l391\">The funding will also enable the company to progress its earlier stage pipeline and follows last year\u2019s seed round of \u00a311m. As part of the financing round, Managing Partner of iGlobe Partners Dr Yoke Sin Chong takes a Board observer role.<\/p>\n\n\n\n<p id=\"viewer-53rr0\">The Trocept approach uses an adenovirus which has been genetically modified by Professor Alan Parker\u2019s laboratory at Cardiff University to exclusively target cancer cells. Accession Therapeutics believes that this makes it the first company to be able to develop therapeutics with a discriminatory viral point of entry into cancer cells. With the virus carrying a transgene coding for one or more agents (such as antitumour or immune activator drugs or prodrugs), this engineered specificity enables the company to target some of the hardest to treat and most widespread forms of the disease, such as breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;We are delighted to have closed so soon this second fundraising round with the support of new investors, including iGlobe Partners, and our existing investors. With the Trocept platform Accession Therapeutics believes it has the ability to create ideal immunotherapies, specific in target and potent in effect with minimal toxicity. We\u2019re focused on advancing our lead programmes to the clinic as rapidly as possible.&#8221;<\/p>\n<cite>Bent Jakobsen, PhD FMedSci, CEO of Accession Therapeutics,<\/cite><\/blockquote>\n\n\n\n<p id=\"viewer-daig1\">Accession Therapeutics\u2019 two lead programmes are each delivering a different therapeutic payload targeted to cancer cells via integrin binding. They are expected to reach the IND stage at the end of 2023 and enter the clinic at the beginning of 2024.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;iGlobe Partners is delighted to support Accession Therapeutics in its strategy to bring about a step change in the effectiveness of cancer immunotherapies. We look forward to working with the company as it develops an exciting pipeline of drug candidates to induce, attract, activate and target broad and potent immune responses against cancer.&#8221;<\/p>\n<cite>Dr Yoke Sin Chong, Managing Partner of iGlobe Partners<\/cite><\/blockquote>\n\n\n        <\/div>\n    <\/div>\n<\/section>\n\n\n    <section class=\"news-archive \" id=\"block_637de1c567d4c\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/oxford\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png 1200w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-300x169.png 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1024x576.png 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-768x432.png 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-1000x563.png 1000w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1-475x267.png 475w\" type=\"image\/png\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2024\/05\/accession1.png\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/24\/accession-therapeutics-awarded\/\" target=\"_self\">\n\t\t\t\tAccession Therapeutics awarded \u20ac7.5m Horizon Europe grant funding to advance TROCEPT-01 (ATTR-01), a first-in-class, tumour-activated immunotherapy\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg 1110w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-300x201.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1024x685.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-768x513.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image-1000x668.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/Garsington-Road-image.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/12\/childbase-partnership-announces-nursery-opening-at-arc-oxford\/\" target=\"_self\">\n\t\t\t\tChildbase Partnership announces new Garsington Road day nursery opening at ARC Oxford\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg 2402w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-300x200.jpg 300w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-768x512.jpg 768w, https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2026\/03\/7df25fe8-e6ff-4960-8f12-8dae8f53943b.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2026\/03\/10\/oxa-raises-103m\/\" target=\"_self\">\n\t\t\t\tOxa Raises $103m in Series D First Close to supercharge Industrial Mobility Automation\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>Accession Therapeutics, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has raised \u00a316.6m to advance its two lead preclinical programmes to clinical trials.<\/p>\n","protected":false},"author":3,"featured_media":1078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[22],"tags":[6210],"class_list":["post-1072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-life-science-and-health"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Accession Therapeutics raises funding - ARC Oxford<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accession Therapeutics raises funding - ARC Oxford\" \/>\n<meta property=\"og:description\" content=\"Accession Therapeutics, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has raised \u00a316.6m to advance its two lead preclinical programmes to clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Oxford\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-23T09:35:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-16T09:11:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"liamjoyce\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"liamjoyce\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\"},\"author\":{\"name\":\"liamjoyce\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\"},\"headline\":\"Accession Therapeutics raises funding\",\"datePublished\":\"2022-11-23T09:35:53+00:00\",\"dateModified\":\"2023-01-16T09:11:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\"},\"wordCount\":420,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\",\"keywords\":[\"Life science and Health\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\",\"name\":\"Accession Therapeutics raises funding - ARC Oxford\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\",\"datePublished\":\"2022-11-23T09:35:53+00:00\",\"dateModified\":\"2023-01-16T09:11:45+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/oxford\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accession Therapeutics raises funding\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"name\":\"ARC Oxford\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\"},\"alternateName\":\"ARC Oxford\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#organization\",\"name\":\"ARC Oxford\",\"alternateName\":\"ARC Oxford\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png\",\"width\":2084,\"height\":2084,\"caption\":\"ARC Oxford\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04\",\"name\":\"liamjoyce\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g\",\"caption\":\"liamjoyce\"},\"url\":\"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/liamjoyce\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accession Therapeutics raises funding - ARC Oxford","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/","og_locale":"en_US","og_type":"article","og_title":"Accession Therapeutics raises funding - ARC Oxford","og_description":"Accession Therapeutics, which is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity, has raised \u00a316.6m to advance its two lead preclinical programmes to clinical trials.","og_url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/","og_site_name":"ARC Oxford","article_published_time":"2022-11-23T09:35:53+00:00","article_modified_time":"2023-01-16T09:11:45+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg","type":"image\/jpeg"}],"author":"liamjoyce","twitter_card":"summary_large_image","twitter_misc":{"Written by":"liamjoyce","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/"},"author":{"name":"liamjoyce","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04"},"headline":"Accession Therapeutics raises funding","datePublished":"2022-11-23T09:35:53+00:00","dateModified":"2023-01-16T09:11:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/"},"wordCount":420,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg","keywords":["Life science and Health"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/","url":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/","name":"Accession Therapeutics raises funding - ARC Oxford","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg","datePublished":"2022-11-23T09:35:53+00:00","dateModified":"2023-01-16T09:11:45+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#primaryimage","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2022\/11\/National-cancer-institute-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/oxford\/blog\/2022\/11\/23\/oxford-based-accession-therapeutics-raises-16-6m-to-advance-cancer-immunotherapy-programmes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/oxford\/"},{"@type":"ListItem","position":2,"name":"Accession Therapeutics raises funding"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/oxford\/#website","url":"https:\/\/www.arcgroup.io\/oxford\/","name":"ARC Oxford","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#organization"},"alternateName":"ARC Oxford","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/oxford\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/oxford\/#organization","name":"ARC Oxford","alternateName":"ARC Oxford","url":"https:\/\/www.arcgroup.io\/oxford\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","contentUrl":"https:\/\/www.arcgroup.io\/oxford\/wp-content\/uploads\/sites\/4\/2025\/06\/ARC-SUBBRANDS-LOGOS-01-OXFORD-1.png","width":2084,"height":2084,"caption":"ARC Oxford"},"image":{"@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/58d00f0e900b593bd191db3b11c19b04","name":"liamjoyce","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/oxford\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a04f7d9ac42ed6cd3a4f60afae284dec8d71c2cfb9df90888ad6368491b71999?s=96&d=mm&r=g","caption":"liamjoyce"},"url":"https:\/\/www.arcgroup.io\/oxford\/blog\/author\/liamjoyce\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/comments?post=1072"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/posts\/1072\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media\/1078"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/media?parent=1072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/categories?post=1072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/oxford\/wp-json\/wp\/v2\/tags?post=1072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}